If you prescribe Pregabalin, a chemist may already have asked for a clearer slip this month. Pregabalin moved to Schedule H1 of the Drugs Rules, 1945, under a notification from the Union Ministry of Health and Family Welfare. The change is in Gazette notification G.S.R. 377(E), dated 13 May 2026 and published in the Official Gazette on 20 May 2026. A Press Information Bureau release two days later set out why, and what retailers and manufacturers must do once the new classification is in force.
This page is for a doctor writing the prescription, and for a clinic or a small hospital that also runs a pharmacy. It separates what the gazette itself does from what the Drugs Rules already said about Schedule H1 medicines, and from what a newspaper has reported about the start date. It is not clinical advice, and it does not tell you when to prescribe Pregabalin or at what dose.
For how to write your name, qualification and registration number on the pad, see how to write your qualifications on a prescription pad. For creating and sharing a typed prescription, see how to create a digital prescription and prescription software.
Information as of 15 November 2026, Asia/Calcutta. This is a general guide, not legal advice. The sections marked "our reading" are not an official checklist. Recheck the current gazette, the CDSCO notice board and, if you retail the medicine, your State Drugs Controller, before you change clinic or pharmacy practice.
The short answer
- What the gazette does. G.S.R. 377(E) inserts "51. Pregabalin" into Schedule H1 of the Drugs Rules, 1945, after serial number 50. It is titled the Drugs (Second Amendment) Rules, 2026.
- When it comes into force. The gazette says the rules "shall come into force after one eighty days from the date of publication of these rules in the Official Gazette." The gazette heading, and the PIB release of 22 May 2026, both give that publication date as 20 May 2026. One hundred and eighty days after 20 May 2026 falls on 16 November 2026. Our reading of "after" those 180 days is set out below. A 31 October 2026 Indian Express report names 12 November, which does not match that arithmetic. We have not seen an official notice that names 12 November.
- It was already a prescription-only medicine, according to PIB. The PIB release says Pregabalin will be regulated under Schedule H1 "instead of the existing Schedule H." Sale by retail only against a prescription of a Registered Medical Practitioner already applied to Schedule H medicines under Rule 65(9)(a). What is new, once the H1 listing is in force, is the stricter H1 record and labelling layer: a separate H1 register at the retailer, kept for three years, and the Schedule H1 caution on the pack.
- What must be on the prescription. Rule 65(10) of the Drugs Rules, 1945 already says, for the purposes of the sale condition in Rule 65(9), that a prescription shall be in writing, signed with the prescriber's usual signature and dated, shall specify the patient's name and address, and shall indicate the total amount of the medicine to be supplied and the dose to be taken. The doctor's name, qualification and registration number come from the ethics regulations, not from G.S.R. 377(E) itself. Those letterhead particulars are explained in our qualifications guide.
- The H1 register is the chemist's record, not a new pad layout. Under Rule 65(3)(1)(h), the retailer records, in a separate register at the time of supply, the name and address of the prescriber, the name of the patient, the name of the drug and the quantity supplied, and keeps that record for three years, open for inspection.
- What Medabha does and does not do. It can print a typed, signed prescription with your name, qualification and registration number, the visit date, the patient's name, and the medicine line you typed, including dose, frequency and duration. It does not flag a medicine as Schedule H or H1, it does not keep an H1 register, and it does not print the patient's address on the slip we inspected.
What the gazette actually does
On 13 May 2026 the Ministry of Health and Family Welfare, Department of Health and Family Welfare, issued notification G.S.R. 377(E). We opened the PDF from the CDSCO Gazette Notifications page on 15 November 2026. The gazette is Extraordinary, Part II, Section 3, Sub-section (i), number 342, headed New Delhi, Wednesday, 20 May 2026. The e-gazette identifier on the same file is CG-DL-E-21052026-272775, and the PDF shows a signature timestamp of 21 May 2026. For the date of publication we follow the gazette heading and the official PIB release, both of which say 20 May 2026.
The notification recites a draft, G.S.R. 54(E) dated 21 January 2026, published on 27 January 2026, on which comments were invited and then considered, and consultation with the Drugs Technical Advisory Board.
The operative part is short. The rules may be called the Drugs (Second Amendment) Rules, 2026. They come into force after 180 days from publication, in the wording quoted above. Then:
"In the Drugs Rules, 1945, in Schedule H1 after serial number 50 and entries relating thereto, the following serial number and entry shall be inserted, namely: 51. Pregabalin."
That is all the gazette adds to the schedule. It does not reprint Rule 65 or Rule 97. It does not set out an H1 register format. It does not list a start date such as 12 November. Those duties already live in the Drugs Rules, and they will apply to Pregabalin once it is in Schedule H1.
The CDSCO notifications page describes the same file as a notification "for amendment in Schedule H1 for inclusion of Pregabalin and its drug formulations." That is the department's heading for the file. The operative line in the gazette is "51. Pregabalin." Our reading of whether salts, combinations and other formulations are covered is flagged below, for a legal read, because we have not quoted a Schedule H1 footnote from the gazette insert itself.
When it comes into force (our reading)
This section is our reading of the dates, not an official calendar entry.
The English text of clause 1(2) is: "They shall come into force after one eighty days from the date of publication of these rules in the Official Gazette." We take "one eighty days" to mean one hundred and eighty days.
PIB's release of 22 May 2026, 10:30 AM, PIB Delhi, titled "Union Health Ministry Brings Pregabalin Under Schedule H1 to Strengthen Regulation and Prevent Misuse," says the notification was "dated 13th May 2026, published in the Gazette of India Extraordinary on 20th May 2026." The PIB text does not name a November date, and it does not restate the 180-day clause.
Counted from 20 May 2026, 180 days later is 16 November 2026. "After" 180 days can be read as completion of that period on 16 November, or as coming into force on the following day, 17 November. We do not choose between those two readings here. As of 15 November 2026, 180 days from the 20 May publication date had not yet elapsed.
The Indian Express, in a Chandigarh report dated 31 October 2026, writes that Pregabalin "will come under stricter regulatory control from November 12" and that over-the-counter sale will be prohibited, with chemists dispensing it only against a valid prescription of a registered medical practitioner. We have used that article only as a secondary report. We have not found, in the gazette or in the PIB release, a sentence that names 12 November. 12 November is also not 180 days after 20 May 2026, and it is not 180 days after 13 May 2026 (that arithmetic ends on 9 November).
Our reading: follow the gazette's 180-day clause and the official publication date of 20 May 2026, and if you need a single calendar date for pharmacy practice, ask your State Drugs Controller in writing, rather than relying on a newspaper date. If a later official circular names a date, that circular is the one to follow, and this page should then be updated from it.
What already applied, and what is new
The PIB release says that, with this notification, Pregabalin "will now be regulated under the stricter provisions of Schedule H1, instead of the existing Schedule H." We use that official sentence for the prior classification. In the CDSCO compilation of the Drugs Rules, 1945 that we opened (file dated 9 September 2024), the word Pregabalin does not appear in the Schedule H or Schedule H1 lists. Gabapentin is listed in Schedule H. G.S.R. 377(E) itself inserts Pregabalin into Schedule H1 and does not, in the text we opened, delete a Schedule H serial. Our reading, for a legal read: treat PIB's "instead of the existing Schedule H" as the ministry's account of the change of class, and do not invent a Schedule H serial number we have not seen.
Sale only on a prescription is not new for a Schedule H medicine. Rule 65(9)(a) already says substances specified in Schedule H and Schedule H1, or Schedule X, "shall not be sold by retail except on and in accordance with the prescription of a Registered Medical Practitioner." So the line that a chemist may sell Pregabalin only against a valid prescription of a registered doctor was already the Schedule H rule, according to PIB's prior classification. The useful change, once the H1 listing is in force, is the tighter H1 layer on top of that.
That layer, already in the Drugs Rules for every H1 drug, includes:
-
A separate H1 register at the retailer. Rule 65(3)(1)(h), in the CDSCO compilation we opened, says the supply of a Schedule H1 drug "shall be recorded in a separate register at the time of the supply giving the name and address of the prescriber, the name of the patient, the name of the drug and the quantity supplied and such records shall be maintained for three years and be open for inspection." The Indian Express describes this more loosely as a separate record of prescriptions and sales, preserved "for the prescribed period." The official period in Rule 65(3)(1)(h) is three years. The H1 register text asks for the prescriber's name and address, the patient's name, the drug and the quantity. It does not, in that clause, ask the chemist to copy the doctor's qualification or registration number into the register, though those particulars still belong on the prescription under the ethics regulations, and they help the chemist identify the prescriber.
-
The pack label. Rule 97(1)(e) requires a medicine that contains a Schedule H1 substance to be labelled with the symbol Rx, in red, on the left top of the label, and with these words in a red rectangular box: "SCHEDULE H1 PRESCRIPTION DRUG - CAUTION", "It is dangerous to take this preparation except in accordance with the medical advice," and "Not to be sold by retail without the prescription of a Registered Medical Practitioner." The PIB release quotes the same caution. That is a manufacturer's labelling duty. It is not something the clinic software prints on the prescription pad.
-
How often the slip may be dispensed. Rule 65(11)(a) says a prescription containing a Schedule H or H1 (or X) drug "must not be dispensed more than once unless the prescriber has stated thereon that it may be dispensed more than once." If you intend a repeat supply from the same slip, that direction has to be written on the prescription. A new, signed prescription for a later visit is a different thing.
PIB also says violations attract action under the Drugs and Cosmetics Act, 1940 and the Rules, and it advises manufacturers, distributors, wholesalers, retailers and pharmacists to follow the notification. We do not add penalties of our own.
The PIB release gives the ministry's reason: reports from certain States of misuse and abuse of Pregabalin, particularly among youth, and seizures of illegally stocked or unauthorisedly sold supplies. It says the drug is prescribed for chronic pain, neuropathies, fibromyalgia and certain neurological conditions, and that it has reportedly been misused for sedative, euphoric and dissociative effects. We repeat that only as the official reason for the change. This page is not a treatment guide, and it does not discuss doses.
What belongs on the prescription (our reading)
G.S.R. 377(E) does not invent a new prescription form. The particulars below already sat in the Drugs Rules and in the ethics regulations. They matter more now because the chemist has to make a separate H1 entry from the slip you write.
The table is a reading aid, not an official form.
| Particular | Where it comes from | On the prescription? | In the H1 register (Rule 65(3)(1)(h))? |
|---|---|---|---|
| In writing, dated, signed with the prescriber's usual signature | Rule 65(10)(a) | Yes | The register is filled at the time of supply; it is not a substitute for a signed, dated slip |
| Patient's name and address | Rule 65(10)(b) | Yes, name and address | Patient's name (that clause does not also list the patient's address) |
| Total amount to be supplied, and the dose | Rule 65(10)(c) | Yes | Quantity supplied |
| Legible drug name | Not as a separate sentence in Rule 65(10); the prescription has to identify the medicine and the amount. A typed name avoids a misread at the counter. | Yes, in practice | Name of the drug |
| Doctor's name, qualification and registration number, including the State Medical Council | The 2002 ethics regulations, as set out in our qualifications guide (clause 7.13 on the pad and the board). Not added by G.S.R. 377(E), and not listed in Rule 65(10) | Yes, on the pad, under those ethics regulations | Prescriber's name and address (not qualification or registration number, in the H1-register clause) |
Our reading, only: write a slip the chemist can record without guesswork. Use a typed drug name and dose where you can. Put the patient's name and address, the date, and your usual signature. Keep your name, qualification and registration number on the letterhead, as the ethics regulations already ask. If you want the same prescription dispensed more than once, say so on the slip; otherwise Rule 65(11)(a) tells the dispenser it may be used only once.
The CDSCO NSAID and antibiotic circular is a separate September 2026 reminder that Schedule H and H1 medicines are not to be sold by retail except under the Drugs Rules. It does not mention Pregabalin. This page is the Pregabalin change; that page is the earlier general reminder.
What to do now (our reading)
This list is our reading for a private OPD, a multi-doctor clinic, or a nursing home or small hospital that may also retail the medicine. It is not an official CDSCO or State Drugs Controller checklist, and it is not clinical advice.
For the doctor writing the prescription
- Check the start date with the gazette, not only with a news report. Use the 180-day clause and the 20 May 2026 publication date, and ask your State Drugs Controller if you need a single date for a pharmacy SOP.
- Keep writing a complete, legible prescription. The H1 move does not, in the sources we opened, add a new pad layout. It does make a thin or undated slip harder for the chemist to record. Name, address, date, signature, medicine, amount and dose, plus your qualification and registration number on the letterhead, are the particulars to have in front of you.
- Do not treat a previous paper pad as automatically wrong. If that pad already carried the ethics-regulation particulars and the Rule 65(10) details, the main change is the chemist's register and the pack label, not a new font on your stationery.
- If you use a typed or WhatsApp copy, the same particulars still have to be on the page the chemist sees. How signing and WhatsApp copies work, and what they are not, is explained in how to create a digital prescription. Medabha does not apply a Digital Signature Certificate.
- If a later visit needs the medicine again, issue a new, signed prescription, or write a clear "may be dispensed more than once" direction on the original slip if that is what you intend. Repeating a previous line in clinic software is not, by itself, a direction on an old slip.
For a clinic, nursing home or small hospital pharmacy that retails Pregabalin
- The H1 register sits with the licensed retailer. Once Pregabalin is in Schedule H1, Rule 65(3)(1)(h) asks for a separate register at the time of each supply, kept for three years and open for inspection. Medabha does not provide that register.
- Sell only against a prescription that meets Rule 65(9) and 65(10). That condition already applied to Schedule H and H1 medicines. Confirm any extra State Drugs Controller direction for your State.
- Watch the pack label as stocks turn over. The red Rx and the Schedule H1 caution box are a manufacturer's duty under Rule 97. Older Schedule H packs in the cupboard may need a plan; we have not seen, in these sources, a line that tells a pharmacy how to relabel stock already on the shelf. Ask the State Drugs Controller or the supplier, rather than inventing a relabel.
- Do not use this page as a reason to stop a patient's medicine. The gazette moves a classification. It does not, in the text we opened, tell a doctor to stop prescribing Pregabalin where it is clinically indicated.
Where Medabha fits, and where it does not
Prescription software in Medabha is built to produce a typed prescription on your letterhead after you sign the visit. On the signed print, the PDF and the picture copy, the repo on main shows:
- The doctor's name, plus the qualification and the registration number and council, when you have entered them under Settings, Letterhead and prescription. An optional HPR ID prints only when that field is filled.
- The visit date (the time the visit was signed, in the clinic's date format).
- The patient's name, and age, sex and phone when those are on the record.
- Each medicine line as you typed or picked it: the drug name (typed, so it is legible), dose, frequency, duration, route and instructions. A generic name can also be printed when that setting is on.
A draft visit cannot be printed. Completing and signing the visit is what locks the prescription. The signature on the page is an image of the drawing you saved under Settings. It is a picture of your usual signature, not a Digital Signature Certificate, and Medabha does not offer DSC signing. That limit is already explained in the digital prescription guide.
What Medabha does not do, and should not be described as doing:
- It does not flag a medicine as Schedule H, Schedule H1 or Schedule X. The central medicine catalog stores a display name, generic name, strength, form and a platform "verified" mark for naming. "Verified" means the platform has reviewed the name. It is not a CDSCO classification, and there is no H1 or H field on the medicine record.
- It does not keep a Schedule H1 register, and it is not a retail-pharmacy register product. If your nursing home or clinic pharmacy retails Pregabalin, that register stays outside Medabha.
- It does not print the patient's address on the prescription slip we inspected. Rule 65(10)(b) asks the prescription to specify the patient's name and address. If the chemist needs the address, add it so that it appears on the copy they see. This is a product gap, not a Rule 65 exception.
- It does not have a separate "total quantity to be supplied" box. It prints the dose, frequency and duration you type. Rule 65(10)(c) asks the prescription to indicate the total amount to be supplied and the dose. If the chemist needs an explicit total quantity, write it on the line, in the instructions, or in another field the chemist will actually see.
- A 1-click refill repeats a previous prescription so you can edit and sign a new visit. That is a new signed prescription. It is not a "dispense more than once" direction written on an earlier slip.
Medabha is built for one doctor per clinic, with an optional receptionist. A multi-doctor nursing home or a small hospital should not treat it as a hospital pharmacy system.
A screenshot to add when you have a real capture from a test clinic (do not invent one): a signed prescription preview or print on the clinic letterhead, showing the doctor's name, qualification and registration number, the visit date, the patient's name, and a typed medicine line with dose, frequency and duration. Suggested path: /images/blog/pregabalin-signed-prescription-letterhead.webp. Suggested alt text: "A signed Medabha prescription on the clinic letterhead, showing the doctor's name, qualification and registration number, the visit date, the patient's name, and a typed medicine line with dose, frequency and duration." Do not add an H1 badge or warning that the product does not show. Do not use a real patient's name.
Sources
- The Gazette of India, Extraordinary, G.S.R. 377(E) dated 13 May 2026, published 20 May 2026, Drugs (Second Amendment) Rules, 2026, adding "51. Pregabalin" to Schedule H1. PDF opened from the CDSCO Gazette Notifications listing (file title: "G.S.R. 377(E)_Notification for amendment in Schedule H1 for inclusion of Pregabalin and its drug formulations") on 15 November 2026: PDF.
- Press Information Bureau, Ministry of Health and Family Welfare, "Union Health Ministry Brings Pregabalin Under Schedule H1 to Strengthen Regulation and Prevent Misuse," posted 22 May 2026, 10:30 AM, PIB Delhi, PRID 2263975.
- Central Drugs Standard Control Organization, compiled The Drugs Rules, 1945, file name dated 9 September 2024, PDF opened on 15 November 2026, in particular Rule 65(3)(1)(h), Rule 65(9), Rule 65(10), Rule 65(11) and Rule 97(1)(e), and the Schedule H and Schedule H1 lists as they stood in that compilation: PDF. This compilation predates G.S.R. 377(E).
- The Indian Express, Kanchan Vasdev, "Pregabalin to come under tighter curbs from Nov 12, Punjab had sought regulation since 2023," Chandigarh, 31 October 2026, article. Used only as a secondary report, and only where we flag the 12 November date and the looser wording of the register period.
What we could not confirm
- An official notice that names 12 November 2026, or any other calendar date, as the day the rules come into force. The gazette uses a 180-day clause from the date of publication.
- Whether "after one eighty days" from 20 May 2026 is 16 November or 17 November 2026. That needs a legal read.
- A Schedule H serial number for Pregabalin in the September 2024 CDSCO compilation, even though PIB describes the prior class as Schedule H.
- A deletion of Pregabalin from Schedule H in G.S.R. 377(E) itself. The gazette only inserts it into Schedule H1.
- An official Schedule H1 footnote, in the gazette insert or in the H1 block of the 2024 compilation as we could extract it, that spells out salts, combinations or "drug formulations." The CDSCO file title uses that phrase; the operative gazette line is "51. Pregabalin." A clinic or pharmacy that is unsure about a combination product should ask the State Drugs Controller.
- Any official instruction on how a pharmacy should handle packs already on the shelf that still carry a Schedule H caution.
- A Medabha feature that flags H1 medicines or keeps the retailer's H1 register. Those features are not in the product on main.
This is a general guide, not legal advice, and not clinical advice. Information as of 15 November 2026, Asia/Calcutta. If a later official notice differs from the documents cited here, follow the notice.
Frequently asked questions
From when is Pregabalin a Schedule H1 medicine?
The gazette does not name a calendar date such as 12 November. G.S.R. 377(E), dated 13 May 2026, says the Drugs (Second Amendment) Rules, 2026 "shall come into force after one eighty days from the date of publication of these rules in the Official Gazette." The gazette heading, and the Press Information Bureau release posted on 22 May 2026, both give that publication date as 20 May 2026. One hundred and eighty days after 20 May 2026 falls on 16 November 2026. Our reading of the word "after" may be 16 November or the next day, 17 November; we do not choose between those two readings here. An Indian Express report dated 31 October 2026 names 12 November, which does not match that arithmetic, and we have not seen an official notice that names 12 November. If you need a single date for pharmacy practice, ask your State Drugs Controller, and follow any later official circular. This is a general guide, not legal advice.
What must be on a Pregabalin prescription now?
G.S.R. 377(E) does not itself set out a new prescription form. Once Pregabalin is in Schedule H1, the sale and prescription conditions already in the Drugs Rules, 1945 apply to it. Rule 65(9)(a) says Schedule H and Schedule H1 substances shall not be sold by retail except on and in accordance with the prescription of a Registered Medical Practitioner. For that purpose, Rule 65(10) says the prescription shall be in writing, signed with the prescriber's usual signature and dated, shall specify the patient's name and address, and shall indicate the total amount of the medicine to be supplied and the dose to be taken. Your name, qualification and registration number, including the State Medical Council, come from the ethics regulations (see our guide on how to write qualifications on a prescription pad), not from this gazette. The chemist's separate H1 register, under Rule 65(3)(1)(h), records the prescriber's name and address, the patient's name, the drug and the quantity supplied, and is kept for three years. This is a general guide, not legal advice.
Does Medabha flag Schedule H1 medicines or keep an H1 register?
No. Medabha does not mark a medicine as Schedule H, Schedule H1 or Schedule X, and it does not keep the retailer's H1 register. What it can do is print a typed prescription, after you sign the visit, with the name, qualification and registration number you entered on the letterhead, the visit date, the patient's name, and the medicine line you typed, including dose, frequency and duration. The central medicine catalog is for names, strengths and forms. A "verified" mark there means the platform has reviewed the name; it is not a CDSCO classification. If your clinic or nursing-home pharmacy retails Pregabalin, the H1 register stays with the licensed retailer, outside Medabha. The printed slip we inspected also does not include the patient's address, which Rule 65(10)(b) asks the prescription to specify, so add the address if the chemist needs it on the copy they see.
Was Pregabalin already a prescription-only medicine?
Yes, according to the official account of the change. The Press Information Bureau release of 22 May 2026 says Pregabalin will now be regulated under Schedule H1 "instead of the existing Schedule H." Rule 65(9)(a) already required Schedule H medicines, like Schedule H1 medicines, not to be sold by retail except on and in accordance with the prescription of a Registered Medical Practitioner. Our reading: the line that a chemist sells Pregabalin only against a valid prescription is not new, if the prior class was Schedule H, as PIB states. What is new, once the H1 listing is in force, is the tighter H1 layer: a separate register at the retailer, kept for three years and open for inspection, and the Schedule H1 caution and red Rx on the pack under Rule 97. This is a general guide, not legal advice, and it is not clinical advice.
Try Medabha in your own clinic
AI medical scribe, WhatsApp prescriptions, specialty charts and a built-in clinic website, set up in minutes.
Start 14-day free trial Prefer a walkthrough? Book a demoNo card needed.
This article is general information about clinic software and documentation workflows, not medical, legal or regulatory advice. Check current requirements with the relevant authority before making compliance decisions.